Companies
/
Alzheon
Healthtech
Alzheon is a clinical-stage biopharmaceutical company developing oral drug candidates aimed at developing investigational drug candidates for Alzheimer’s disease.
Create an account to view live offerings, pricing, and market activity.
Sign in to view offerings and live market activity.
Alzheon was founded in 2013 by Martin Tolar, a physician-scientist, building on research originally developed at Harvard Medical School and Massachusetts General Hospital into a molecule intended to selectively stabilize toxic amyloid beta oligomers, one of the proteins widely implicated in the buildup of plaques associated with Alzheimer's disease. The company's lead candidate, an oral small-molecule drug marketed under the name ALZ-801, is designed as a prodrug of tramiprosate, an earlier compound studied in Alzheimer's research, reformulated to improve its pharmacological properties and specifically targeted at patients who carry certain genetic risk variants, such as two copies of the APOE4 gene, that put them at especially high risk of developing the disease. Alzheon has positioned ALZ-801 as a potential oral alternative to the antibody infusion therapies, such as those developed by Biogen and Eisai or Eli Lilly, that have recently reached the Alzheimer's drug market but require regular infusions and carry certain safety monitoring requirements related to brain swelling and bleeding. As an oral pill, Alzheon's candidate would in principle be easier for patients to take regularly and potentially more scalable for widespread use if its clinical trial results hold up. The company has run Phase 3 clinical trials of ALZ-801 in genetically defined patient populations and has published data suggesting a slowing of cognitive decline alongside a favorable safety profile relative to antibody therapies. Alzheon has raised funding from investors including Alzheon's own founders and outside biotech investors, and continues to advance its regulatory filings with the U.S. Food and Drug Administration as it seeks approval, competing in a rapidly evolving Alzheimer's treatment landscape that now includes several approved and late-stage therapies from much larger pharmaceutical companies.
FOR QUALIFIED INSTITUTIONAL AND ACCREDITED INVESTORS ONLY: Under federal securities laws, private market investments on this platform are available exclusively to Institutional and Accredited Investors. Verification of status required before investing. Private investments involve significant risks including illiquidity, potential loss of principal, and limited disclosure requirements. "Augment" refers to Augment Markets, Inc. and its affiliates. Augment Markets, Inc. is a technology company offering software and data services, not a bank or financial institution. Cash Accounts are provided by Modern Treasury Corp. financial institution partners and through Augment's technology. Augment does not act as a money services business, provide money transmission, or serve as a custodian of funds. Funds held in your Cash Account are not FDIC insured unless expressly disclosed. Full terms available in the Augment Cash Account Agreement. Brokerage services are offered through Augment Capital, LLC, an affiliated broker-dealer and member FINRA/SIPC. "Investment accounts" are not brokerage accounts and do not hold customer funds or securities. Investment advisory services are offered through Augment Advisors, LLC, an SEC-registered investment adviser. Registration with the SEC does not imply a certain level of skill or training. Neither Augment Advisors, LLC nor Augment Capital, LLC provide legal or tax advice; consult your attorney or tax professional regarding your specific situation. For additional information, please refer to Augment Advisors, LLC's Form ADV Part 2A (Firm Brochure) and FINRA BrokerCheck.
No news available for this company.
